correcting moderate to severe nasolabial folds. Used for cosmetic and medical reconstructive purposes in the treatment of e.g. facial lipoatrophy, debilitating scars or morphological asymmetry
1 box of 1 mL syringe, Needle: 2 x 30G ½” thin wall Terumo™ needles (CE 0197)
For correcting moderate to severe nasolabial folds. Used for cosmetic and medical reconstructive purposes in the treatment of e.g. facial lipoatrophy, debilitating scars or morphological asymmetry.
Est. duration in the skin
Arruda LHF, Costa A, Pereira ESP, de Oliveira Pereira M, Assumpcao EC (2013) Evaluation of Clinical Safety and Effectiveness of Hyaluronic Acid-based Temporary Dermal Filler Used in Nasolabial Folds. J Clin Exp Dermatol Res 4: 196. doi:10.4172/2155-9554.1000196,2 Kopera, D., Ivezic-Schoenfeld, Z., Federspiel, I. G., Grablowitz, D., Gehl, B., & Prinz, M. (2018). Treatment of facial lipoatrophy, morphological asymmetry, or debilitating scars with the hyaluronic acid dermal filler Princess. FILLER. Clinical, cosmetic and investigational dermatology, 11, 621–628. doi:10.2147/CCID.S181964, saypha. FILLER was previously known as Princess. FILLER
2.3 % (23 mg/mL)
High molecular weight hyaluronic acid of non-animal origin
BDDE (concentration ≤ 2 ppm)
Phosphate buffer, NaCl
• to provide the skin with an optimum supply of moisture, thus alleviating visible dryness and lack of elasticity
• to restore lost radiance and vitality to tired, jaded skin
• to improve the skin’s hydration, tone and elasticity
• to create a fresher, healthier complexio
3 sessions at intervals of 2–3 weeks, then as required
Innovative
matrix - crosslinking
technology
Intensive research and development combined with decades of process optimisation led to the new proprietary macro (matrix crosslinking) technology for processing hyaluronic acid to reach stable and longlasting HA fillers.
3 steps
Pretreatment of
hyaluronic acid
Crosslinking
Purification and mixing
Pretreatment of
Hyaluronic acid
• Starting point: high molecular weight hyaluronic acid
• Controlled fracturing process for a part of the utilized HA
• Result: a high diversification level of the starting material
Beside the high molecular weight HA Croma adds HA fragments with varying chain length. This is the basis for the upcoming crosslinking step.
Crosslinking
• Highly efficient crosslinking process using BDDE
• BDDE links the diversified HA fragment to create a stable HA network
Croma Syringe
